Eli Lilly and Company (LLY)
Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
Eli Lilly said it will spend $6 billion to build a manufacturing plant in Huntsville, Alabama, to help boost production of its closely watched experimental obesity pill, orforglipron, and other drugs. It is the third facility in a string of new planned U.S. investments by the drugmaker.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Eli Lilly's Mounjaro added to China's state insurance list for diabetes treatment
Eli Lilly's popular drug Mounjaro will be added to China's state-run health insurance scheme from January 1 for patients with type 2 diabetes, the National Healthcare Security Administration said in a website notice on Sunday.
Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website
Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple doses.
Eli Lilly cuts price of Zepbound in heightened weight-loss drug competition
Eli Lilly and Co (NYSE:LLY) said on Monday it is lowering the cash prices of its weight-loss drug Zepbound, marking the latest move in a growing price battle with rival Novo Nordisk. The US pharmaceutical giant said single-dose vials of Zepbound will now be available on its direct-to-consumer platform, LillyDirect, at reduced prices.
Eli Lilly cuts Zepbound price to widen access for obesity drug
Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S. patients, as demand for weight-loss therapies surge.
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
Eli Lilly said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect. Starting Dec. 1, cash-paying patients with a valid prescription can pay $299 to $449 per month for Zepbound vials on LillyDirect, depending on the dose, down from a previous range of $349 to $499 per month.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026
Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.
A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling
In the last part of November 2025, Eli Lilly and Company NYSE: LLY shattered a historic ceiling. The Indianapolis-based drugmaker became the first pharmaceutical company to reach a market capitalization of $1 trillion.
